| Summary of Disaggregated Segment Expenses Split between R&D and G&A Costs |
The following table presents the significant segment expenses for the three months ended March 31, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2026 |
|
|
2025 |
|
Research and development expenses: |
|
|
|
|
|
|
Clinical and development costs |
|
$ |
8,280 |
|
|
$ |
10,537 |
|
Preclinical costs |
|
|
(65 |
) |
|
|
1,238 |
|
Personnel and related costs |
|
|
3,175 |
|
|
|
7,563 |
|
Stock-based compensation expense |
|
|
1,201 |
|
|
|
3,005 |
|
Other research costs |
|
|
1,015 |
|
|
|
1,545 |
|
Total research and development expenses |
|
|
13,606 |
|
|
|
23,888 |
|
General and administrative expenses: |
|
|
|
|
|
|
Personnel and related costs |
|
|
1,841 |
|
|
|
2,825 |
|
Stock-based compensation expense |
|
|
1,308 |
|
|
|
2,211 |
|
Other general and administrative costs |
|
|
2,211 |
|
|
|
2,896 |
|
Total general and administrative expenses |
|
|
5,360 |
|
|
|
7,932 |
|
Loss from operations |
|
|
(18,966 |
) |
|
|
(31,820 |
) |
Interest income |
|
|
1,182 |
|
|
|
1,483 |
|
Interest expense |
|
|
(331 |
) |
|
|
(406 |
) |
Other income (expense), net |
|
|
188 |
|
|
|
(11 |
) |
Net loss |
|
$ |
(17,927 |
) |
|
$ |
(30,754 |
) |
|